Gilead Sciences’ Biktarvy, a three-component antiviral, suppressed HIV infections in 99 percent of patients who took it as part of two phase 3 studies. There were no treatment failures, the company reported at the 24th International AIDS Conference in Montreal.
Source: Drug Industry Daily